Cellectar Biosciences (CLRB) Operating Leases (2019 - 2026)
Cellectar Biosciences (CLRB) posted Operating Leases of $309397.0 for Q4 2025, down 7.89% sequentially from $335895.0 in Q3 2025, and down 24.46% YoY from $409586.0 in Q4 2024.
Cellectar Biosciences (CLRB) Operating Leases (2019 - 2026) Analysis & Trends
Cellectar Biosciences has reported Operating Leases for 7 years, with the latest figure at $309397.0 in Q4 2025.
- Quarterly Operating Leases fell 24.46% year-over-year to $309397.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $309397.0 (down 24.46% YoY) and the FY2025 annual result came in at $309397.0, down 24.46% from the prior year.
- Operating Leases fell to $309397.0 in Q4 2025 per CLRB's latest filing, from $335895.0 in the prior quarter.
- Over five years, Operating Leases peaked at $552981.0 in Q4 2022 and troughed at $53769.0 in Q3 2022.
- A 5-year average of $357589.8 and a median of $389601.5 in 2021 frame the typical range for Operating Leases.
- The sharpest annual moves came in 2022 and 2023: Operating Leases slumped 73.38% in 2022, then jumped 853.62% in 2023.
- Over 5 years, Operating Leases stood at $166292.0 in 2021, then soared by 232.54% to $552981.0 in 2022, then dropped by 10.67% to $494003.0 in 2023, then dropped by 17.09% to $409586.0 in 2024, then dropped by 24.46% to $309397.0 in 2025.
- According to Business Quant data, Operating Leases over the past three periods registered $309397.0, $335895.0, and $361487.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.90 Bn | 131.05 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 86.10 Bn | 78.11 Bn | 3.93 Bn |
| 3 | Argenx Se | 65.56 Bn | 60.37 Bn | 1.37 Bn |
| 4 | Moderna | 55.82 Bn | 50.68 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 42.14 Bn | 37.04 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.67 Bn | 28.36 Bn | 992.69 Mn |
| 7 | BioNTech SE | 27.74 Bn | 9.35 Bn | 668.28 Mn |
| 8 | Insmed | 27.53 Bn | 26.37 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.38 Bn | 26.54 Bn | - |
| 10 | Cellectar Biosciences | 6.70 Mn | 6.70 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 1.53 Mn |
| Dec 31, 2025 | 309,397.00 |
| Sep 30, 2025 | 335,895.00 |
| Jun 30, 2025 | 361,487.00 |
| Mar 31, 2025 | 386,203.00 |
| Dec 31, 2024 | 409,586.00 |
| Sep 30, 2024 | 431,929.00 |
| Jun 30, 2024 | 531,000.00 |
| Mar 31, 2024 | 474,349.00 |
| Dec 31, 2023 | 494,003.00 |
| Sep 30, 2023 | 512,750.00 |
| Jun 30, 2023 | 530,856.00 |
| Mar 31, 2023 | 548,344.00 |
| Dec 31, 2022 | 552,981.00 |
| Sep 30, 2022 | 53,769.00 |
| Jun 30, 2022 | 92,214.00 |
| Mar 31, 2022 | 129,714.00 |
| Dec 31, 2021 | 166,292.00 |
| Sep 30, 2021 | 201,970.00 |
| Jun 30, 2021 | 236,058.00 |